Corcept Therapeutics Reports NDA Submission of Relacorilant to the US FDA for Treating Hypercortisolism
Shots:
- Corcept has submitted NDA of relacorilant to the US FDA for the treatment of endogenous hypercortisolism (Cushing’s syndrome)
- Submission was based on pivotal GRACE study, confirmatory P-III (GRADIENT) & long-term extension trials plus P-II hypercortisolism trial. Relacorilant showed improved symptoms without adrenal insufficiency, hypokalemia, QT prolongation, or progesterone receptor-related AEs (endometrial thickening or vaginal bleeding)
- Relacorilant is a selective cortisol modulator that targets the glucocorticoid receptor. It is also being studied for cancers like ovarian, adrenal & prostate other than hypercortisolism
Ref: Corcept Therapeutics | Image: Corcept Therapeutics
Related News:- Corcept Concludes Patient Recruitment in the P-II Study of Dazucorilant for Amyotrophic Lateral Sclerosis (ALS)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
